

1 **Dimeric immunoglobulin A as a novel diagnostic marker of measles infection**

2 DlgA: a new diagnostic marker for measles

3
4 Khayriyyah Mohd Hanafiah^{1,3*}, Joanne Hiebert², Vanessa Zubach², Alberto
5 Severini^{2,4}, David A. Anderson¹, Heidi E. Drummer^{1,5,6}

- 6
7 1. Life Sciences, Macfarlane Burnet Institute, 85 Commercial Rd 3004
8 Melbourne VIC Australia
9 2. Viral Exanthemata and STD Section, National Microbiology Laboratory, Public
10 Health Agency of Canada, Winnipeg, Manitoba, Canada
11 3. Department of Biology, School of Arts and Sciences, St John Fisher
12 University, Rochester, United States
13 4. Department of Medical Microbiology and Infectious Diseases, Faculty of
14 Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
15 5. Department of Microbiology, Monash University, Australia
16 6. Department of Microbiology and Immunology at the Peter Doherty Institute for
17 Infection and Immunity, University of Melbourne, Australia.

18
19
20
21 *Corresponding Author:

22 Khayriyyah Mohd Hanafiah smohdhanafiah@sjfc.edu

23 24 **Abstract**

25
26 Despite tremendous measles incidence reduction through universal vaccination,
27 elimination efforts rely on improved surveillance. Detection of anti-measles
28 immunoglobulin M (IgM) by ELISA is the standard laboratory diagnostic method.
29 However, true infection is rare and seroconversion following MMR vaccination also
30 generates IgM, which results in low positive predictive values of assays in elimination
31 settings, thus necessitating confirmatory testing. Improved diagnostic tests for
32 measles infection are a World Health Organization (WHO) research priority. We
33 investigated whether dimeric immunoglobulin A (dlgA), the predominant antibody
34 produced in mucosal immunity, may be a marker of recent or acute measles infection.
35 We examined a serological panel of confirmed measles infection (anti-measles IgM
36 positives, n=50), and non-measles infection with rubella (n=36), roseola (n=40),
37 chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever-rash illness of
38 unknown cause (n=37). Sera were examined on a Micromune anti-measles IgM,
39 Euroimmun anti-measles virus lysate (VL) and nucleoprotein (NP) IgM kits. Assays
40 were then modified to detect dlgA using an in-house protocol based on a recombinant
41 chimeric secretory component protein and anti-secretory component monoclonal
42 antibody. We observed significantly higher levels of anti-measles VL dlgA in measles

43 samples than non-measles controls ($p < 0.001$), and there was low correlation with IgM
44 (R^2 : 0.01, p value: 0.487). Unlike IgM, dIgA reactive to measles NP was not detected
45 in most samples. Comparable diagnostic potential of anti-measles dIgA (AUC 0.920 -
46 0.945) to anti-measles IgM (AUC 0.986 – 0.995), suggests that dIgA may be a new
47 blood-based marker of acute measles, independent of IgM, which merits further
48 investigation and optimization.

49
50

51 **Introduction**

52

53 Measles morbillivirus is a single stranded, enveloped, negative sense RNA
54 paramyxovirus that is a significant cause of childhood morbidity and mortality (1). The
55 incidence of measles infection has declined due to high vaccine coverage. However,
56 risks of sporadic community outbreaks have increased particularly in subpopulations
57 with lower childhood vaccine coverage, even in settings where measles has been
58 eliminated in the general population (2). Additionally, breakthrough infections from
59 primary and secondary vaccination failure due to non-response or waning immunity
60 have been reported (3–6). Sustained elimination efforts hinge on improved
61 surveillance (7). Thus, development, evaluation and scale up of improved diagnostics
62 including point-of-care rapid diagnostic tests to enable timely detection is a key WHO
63 research priority (1).

64 Currently, clinical symptoms of viral fever and rash, and history of exposure
65 followed by detection of anti-measles immunoglobulin M (IgM) by ELISA, is the
66 standard method of diagnosis. In outbreak investigations, detection of viral RNA
67 through reverse transcriptase polymerase chain reaction (RT-PCR) (8) or IgG avidity
68 assays (9) to confirm IgM results may be required. IgM “true” positivity may arise
69 following MMR vaccination (10) and commercial IgM ELISAs have varied accuracy
70 and low positive predictive values in elimination settings (11, 12).

71 Dimeric IgA is the predominant antibody class produced at mucosal surfaces,
72 and hence, an important part of the early immune response to infection that involve
73 the mucosa (13). In respiratory diseases such as COVID-19 and measles (14, 15),
74 studies typically measured secreted dIgA or secretory IgA (sIgA) in saliva, nasal
75 washes or bronchoalveolar fluid. By contrast, IgM is the antibody class produced as
76 part of the primary humoral response to antigen (regardless of source) prior to class
77 switching and affinity maturation yielding IgG and IgA antibodies. Anti-measles IgM is
78 produced in response to both acute infection as well as MMR vaccination, and is
79 detectable in blood from 7 days up to 8 weeks post-infection and coincides with rash
80 onset.

81 We have previously shown that virus-specific dIgA is a promising blood-based
82 biomarker of acute infection in hepatitis A and hepatitis E infections (16). Longitudinal
83 observations in patients with hepatitis C and COVID-19 suggest that dIgA from natural
84 infection is transiently detectable in blood from 7 - 100 days (16, 17). In particular, data

85 from a prospective study of dIgA response in COVID-19 suggest that dIgA from natural
86 infection is transiently detectable from 7 - 100 days (~14 weeks), and unlike IgG and
87 IgA responses which are sustained (18).

88 Considering that measles begins as a respiratory (mucosal) infection, we
89 hypothesised that anti-measles dIgA may be a serological marker of recent or acute
90 measles infection that is distinct and complementary or superior to the detection of
91 anti-measles IgM. While previous studies have relied on measuring sIgA in secretions
92 to investigate mucosal responses, we previously established the use of a chimeric
93 secretory component protein in an indirect enzyme-linked immunoassay (ELISA) that
94 allowed selection of antigen-specific dimeric/polymeric IgA from total IgA in serum (16,
95 17), which otherwise is predominantly monomeric and not reflective of mucosal
96 immunity. Using this unique ELISA for dIgA detection, we show that i) anti-measles VL
97 dIgA, but not anti-measles NP is detectable in levels higher than IgM in confirmed
98 acute measles serum/plasma samples; ii) the anti-measles VL dIgA response is not
99 quantitatively correlated with anti-measles IgM response and; iii) the diagnostic
100 potential of anti-measles dIgA (AUC 0.920 - 0.945) is comparable to anti-measles IgM
101 (AUC 0.986 – 0.995), albeit cross-reactivity observed in samples of patients with other
102 viral exanthematous infections resulted in lower assay specificity, which may be
103 improved with further assay optimization.

104

105 **Materials and Methods**

106

107

108 Samples

109

110 Preliminary studies were conducted on a well-described multi-timepoint commercial
111 panel of confirmed measles cases (n=9), from outbreaks in Czech Republic (Biomex
112 GmbH, Germany), a WHO proficiency test control panel (acute
113 rubella/parvovirus/dengue n=8; measles/rubella uninfected (confirmed IgM
114 negative)=19) kindly provided by Victorian Infectious Disease Reference Laboratory
115 (VIDRL) (Melbourne, Australia), and archived healthy donor (n=88) samples.

116

117 Results were validated by testing on a study panel comprising anonymized residual
118 sera referred to the National Microbiology Lab (NML) (Winnipeg, Canada) for
119 serological testing and included sera from laboratory confirmed measles cases,
120 (n=50), and sera with provisional diagnosis of rubella (n=36), roseola (n=40),
121 chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever and rash illness
122 of unknown etiology (n=37). This complete panel was previously used to evaluate
123 the diagnostic accuracy of commercial assays for the detection of measles-specific
124 IgM antibodies (11).

125

126 ELISA

127

128 *In-house measles VL antigen plate preparation*

129

130 A batch of antigen measles Edmonston strain virus lysate (Zeptomatrix, NY, USA)
131 were coated on F8 Maxisorp Nunc™ (Thermo Scientific) microtiter plates following
132 an in-house sucrose stabilized ELISA plate coating protocol. Briefly, lysate was
133 diluted in bicarbonate pH 9.2 coating buffer at 2.5 µg/mL, dispensed at 50 µL/well,
134 incubated on a plate shaker at ambient temperature (AT) for 30 minutes and then
135 placed in a humidified lunchbox at 2-8°C for overnight incubation. Next day, the
136 coating solution was tipped out and 200 µL/well of 5% skim milk in PBS was added
137 to unwashed plates and incubated at AT for 2 hours to block the plates. A 5%
138 sucrose solution was then added to blocked plates and incubated for 10 mins at AT.
139 The sucrose solution was flicked out and allowed to air dry in a 37°C incubator for 3
140 hours, then placed in labelled aluminium foil pouches with desiccant, and stored at 2-
141 8°C.

142

143 *Commercial IgM kits and modification for dIgA detection*

144

145 Commercial assays for the detection of IgM subclass antibodies specific to measles
146 virus included Euroimmun measles IgM (cat # EI 2610-9601M, Medizinische
147 Labordianostika AG, Lübeck, Germany), Euroimmun measles NP (cat # EI 2610-
148 9601-4M, Medizinische Labordianostika AG, Lübeck, Germany) and Microimmune
149 IgM (cat# MeVM010 Clin-Tech Ltd., Guildford, UK). IgM ELISAs were performed
150 according to manufacturers' protocols.

151

152 For detection of anti-measles dIgA, in-house lyophilized chimeric secretory
153 component (cSC) protein and anti-secretory component (anti-SC) antibody as
154 previously described (17, 18) were used in an indirect ELISA. Briefly, strips prepared
155 in-house and commercial pre-coated antigen strips (Euroimmun/Euroimmun NP kits)
156 were blocked with 1.5% bovine serum albumin for 1 hour at 37°C in a humidified
157 environment. Then, 4 µg/mL of cSC was added to Euroimmun sample buffer and the
158 serum/plasma was diluted at a ratio of 1:101 in the cSC-buffer mixture then
159 incubated for 10 minutes to allow for cross-absorption of IgG. To allow for cSC-dIgA
160 complex to bind the antigen on the plate 100 µL/well of cSC/sample mixture was
161 added to the antigen coated strips and incubated overnight at 2-8°C. A volume of
162 100 µL/well of mouse anti-SC at 0.5 µg/mL was added and the plate was incubated
163 for 1 hr at 37°C. A volume of 100 µL/well of anti-mouse IgG horseradish peroxidase
164 (HRP) conjugate (cat# A16078, Invitrogen) at a 1:2000 dilution was added and
165 incubated for 1 hr at 37°C. Between each step, plates were washed with 450µl of
166 0.05% PBS Tween-20 thrice with a 30 delay before aspirating using a BioTek 50TS
167 96-well plate waster. Finally, 100 µL/well of Euroimmun tetramethylbenzidine (TMB)
168 substrate was added to the wells. In-house prepared strips were incubated for 10

169 mins and Euroimmun strips were incubated for 15 mins in the dark. The reactions
170 were stopped with 100 μ L/well Euroimmun Stop solution containing 0.5M sulphuric
171 acid. Optical densities were read with a Tecan sunrise microplate absorbance reader
172 immediately after the addition of the stop solution. The plates were slightly shaken
173 and read at a wavelength of 450nm with a reference wavelength of 650nm. Optical
174 density data were exported to a Microsoft Excel file for calculations and result
175 determinations.

176

177

178 Statistical analysis

179

180 Replicate optical density (OD) values were averaged, coefficient of variation (CV)
181 was calculated to ensure acceptability (<15%), and S/Co values were calculated by
182 dividing average sample OD with average calibrator OD using Microsoft Excel.
183 Positive cut-off values for in-house assays were based on average OD or S/Co of
184 non-measles plus 2 standard deviations, and for commercial kits following
185 manufacturers' instructions. Kruskal-Wallis comparison of anti-measles dIgA and IgM
186 reactivity across multiple sample groups followed by pairwise Mann-Whitney U or
187 Welch's t-test post-hoc analysis, Pearson correlation of anti-measles dIgA and IgM
188 reactivity in measles sample group, area under curve (AUC) analysis comparing
189 measles and non-measles samples for dIgA and IgM were performed on GraphPad
190 Prism v.9.3 All statistical analyses were conducted two-tailed with alpha set at 0.05,
191 and a p value of <0.05 considered statistically significant, except for correlation
192 which was Bonferonni-adjusted to <0.01 for multiple comparisons.

193

194 **Results**

195

196 Anti-measles VL dIgA but not anti-measles NP detected in all patients with confirmed 197 acute infection

198

199 Confirmation of clinical symptoms and history of exposure to measles using a
200 laboratory-based anti-measles immunoglobulin M (IgM) ELISA is the standard
201 method of diagnosis. Several commercial assays of varying accuracy exist to detect
202 anti-measles IgM, including those against virus lysate and nucleoprotein (11). To
203 determine whether we could detect anti-measles dIgA, we employed a modified
204 indirect ELISA protocol using Euroimmun kits as well as in-house measles virus
205 lysate coated plates for detection of antigen-specific dIgA in plasma of individuals
206 with acute measles infection and other viral exanthema conditions.

207

208 We first observed high anti-measles VL dIgA reactivity in the commercial panel of
209 acute measles infection samples, which were significantly higher (Kruskal Wallis p
210 <0.0001, Welch's t-test p<0.0001) than in healthy donors, acute

211 rubella/parvovirus/dengue infected and measles/rubella uninfected (IgM negative)
 212 samples, comparable to IgM reactivity as measured using commercial anti-measles
 213 VL kits from Euroimmun (Figure 1). In addition, we saw a significant difference in
 214 anti-measles VL dIgA versus IgM reactivity for individual samples (paired t-test p:
 215 0.026).


216

217 When the assay was repeated in a larger panel of acute measles samples, we
 218 observed elevated levels of anti-measles VL dIgA compared to controls, albeit lower
 219 than anti-measles VL dIgA reactivities measured in the earlier commercial panel or
 220 using anti-measles IgM (Figure 2). While anti-measles VL dIgA reactivity was
 221 observed in all measles samples on both in-house plates precoated with measles
 222 virus (Edmonston strain) lysate (Zeptomatrix, NY, USA) and the commercial measles
 223 IgM precoated antigen plate (Euroimmun), the absorbance values were significantly
 224 higher in assays run on the in-house antigen plates (Wilcoxon $p < 0.0001$). Notably
 225 however, only 18% (9/50) acute measles infection samples were above positive cut-
 226 off value for anti-measles NP dIgA, unlike anti-measles NP IgM, where 80% (40/50)
 227 of the samples were considered positive for measles according to manufacturer cut-
 228 off.

229

230

231




232

233

234 Figure 1. Preliminary screening of Biomex vs VIDRL shows a) significantly elevated
 235 anti-measles VL dIgA S/Co or S/Cal ratios in measles samples compared to control
 236 samples, comparable to b) anti-measles VL IgM as determined using a Kruskal-
 237 Wallis test followed by Welch's t-test post hoc; with c) individual acute measles
 238 samples showing significantly different levels of anti-measles VL dIgA vs IgM on
 239 paired t-test. Asterisks (****) denote statistical significance across all groups at
 240 $p < 0.0001$.

241
242
243
244
245
246
247
248
249
250
251
252




253
254
255
256
257
258

Figure 2. Scatterplot of measles (open circles, n=50) and non-measles (open diamonds, n=189) reactivities in OD units across assays. Asterisks (****) above line denotes statistical significance at $p < 0.0001$, two-tailed as determined by Welch's t test.

259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276

Anti-measles VL dIgA and IgM responses are independent

While the high levels of anti-measles dIgA in acute samples confirms the presence of this marker in measles infection, we wanted to determine whether the dIgA response was independent from the IgM response, and thus providing a different dimension of diagnostic information. Hence, we performed a correlation analysis between the reactivity of anti-measles dIgA versus anti-measles IgM in measles samples. The correlation scatterplots (Figure 3) demonstrate that while overall anti-measles VL dIgA reactivity is comparable to anti-measles VL IgM in patients with confirmed measles infection, individual patient responses are variable with most patients having either higher anti-measles VL dIgA or anti-measles VL IgM. Correlation and heatmap analysis suggests that anti-measles VL dIgA reactivity in patients is not quantitatively correlated with anti-measles VL IgM. Despite much lower reactivity of anti-measles NP dIgA among measles infected individuals, these levels appear to be significantly correlated with levels of anti-measles VL dIgA.



277
 278 Figure 3. XY plots of antibody reactivity among acute measles samples (n=50)
 279 shows low correlation between IgM and dIgA markers, but significant correlation
 280 between anti-measles VL dIgA and anti-measles NP dIgA. Heat map (bottom left)

281 summarizes correlation of anti-measles IgM and dIgA evaluated in measles (n=50)
 282 samples based on Pearson r values, showing inverse relationship (shade of blue)
 283 between anti-measles VL dIgA (on in-house plate) and Euroimmun anti-measles NP
 284 IgM, albeit not reaching statistical significance. Asterisks denote statistical
 285 significance of r values based on $p < 0.05$ (*), < 0.01 (**), < 0.001 (***) and < 0.0001
 286 (****)

287
 288

289 Higher reactivity of anti-measles VL dIgA compared to IgM in measles patients, but
 290 lower diagnostic potential due to cross-reactivity in non-measles controls

291

292 Noting the challenge of comparing an in-house assay to optimized commercial
 293 assays, we wanted to determine the diagnostic value of the dIgA assays at its
 294 present iteration. Due to the lower dIgA reactivity observed against NP, we only
 295 evaluated diagnostic potential of anti-measles VL dIgA against commercial IgM
 296 assays.

297

298 Although, we observed high reactivity of anti-measles dIgA in acute measles on both
 299 in-house VL and Euroimmun VL plates, comparison of diagnostic potential using
 300 receiver-operator curves (ROC) shows that the current dIgA assays under
 301 development have yet to reach accuracy comparable to the commercial assays. The
 302 anti-measles VL dIgA assay on the Euroimmun VL plates recorded a higher AUC
 303 (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the in-
 304 house plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower
 305 ODs. This is likely due to the high cross-reactivity in a small proportion of false
 306 positive non-measles samples. The AUC value for anti-measles VL dIgA was
 307 significantly inferior to its IgM counterparts, with anti-measles VL IgM having the
 308 highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP
 309 IgM had the lowest AUC values among the commercial IgM assays (0.986, 95% CI:
 310 0.973-0.999), overlapping the lower end of the confidence interval for anti-measles
 311 VL dIgA assay on Euroimmun VL plates (Table 1).

312
 313
 314

315 Table 1. Area under receiver-operator curves (AUC) values and sensitivity of
 316 assays*

Assay	AUC (95% CI)	Sensitivity at ~95% specificity (95% CI)	Specificity at ~95% sensitivity (95% CI)
Anti-measles VL dIgA (in-house)	0.920 (0.882 – 0.959)	58% (44 – 71%)	71% (65 – 77%)
Anti-measles VL dIgA (Euroimmun)	0.948 (0.917 – 0.980)	76% (63 – 86%)	69% (62 – 75%)

Anti-measles VL IgM (Euroimmun)	0.995 (0.990 – 1.000)	100% (93 – 98%)	96% (93 – 98%)
Anti-measles NP IgM (Euroimmun)	0.986 (0.973 – 0.999)	96% (87 – 99%)	96% (93 – 98%)
Anti-measles IgM (Microimmune)	0.993 (0.984 – 1.000)	98% (90 – 100%)	93% (69 – 100%)

317 *Note: Anti-measles VL dIgA were performed using in-house protocol on Euroimmun
318 precoated antigen plates. Anti-measles IgM assays were performed according to
319 manufacturer’s protocol. AUC values were analysed using OD units with the
320 Wilson/Brown method for determining confidence interval on GraphPad Prism v9.3.
321
322
323
324

325 Discussion

326
327 Rapid and accurate diagnostic tests are crucial tools contributing towards measles
328 elimination (1). While standard IgM-based serological tests exist to confirm measles
329 infection, low positive predictive values in low prevalence settings necessitates
330 discovery of alternative diagnostic markers (11, 12). A key challenge to further
331 biomarker discovery and diagnostic development is the fact that measles has been
332 eliminated in many parts of the world. Even in many countries where elimination
333 status is compromised, there is extremely low prevalence of measles except during
334 outbreaks. For example, in elimination settings such as Australia, 289 cases were
335 reported in 2019 (19), which makes it is challenging to obtain sufficient numbers of
336 true positive samples.
337

338 Nevertheless, a key strength of this study is the relatively large sample size of true
339 positives (n=50) that were evaluated, following their collection from laboratory
340 confirmed cases associated with measles outbreaks in Canada (11). Furthermore,
341 we included samples from patients with provisional diagnosis of several different viral
342 exanthematous conditions that are known to be sources of cross-reactivity such as
343 rubella and roseola (20). With access to these samples, we aimed to determine the
344 diagnostic potential of anti-measles dIgA, an important but under investigated
345 component of antibody response to many mucosal infections such as measles.
346

347 Using an in-house indirect ELISA protocol for dIgA detection (18) on in-house pre-
348 coated VL antigen plates and commercial plates, we observed the presence of anti-
349 measles VL dIgA in levels as comparably high as IgM in two independent panels of
350 confirmed acute measles serum/plasma samples (Figure 1, 2). Although the
351 distribution of anti-measles VL dIgA in measles samples was significantly higher than
352 non-measles controls on both in-house pre-coated antigen plates and Euroimmun

353 pre-coated antigen plates, the reactivity of measles samples in the latter was much
354 lower. While being significantly higher in measles compared to non-measles
355 controls, we did not observe much, if any dIgA reactivity against measles NP antigen
356 in a majority of the measles samples (Figure 2). Additionally, while correlation and
357 heatmap analysis demonstrated that the anti-measles VL dIgA response has low
358 correlation and thus is independent from anti-measles IgM (Figure 3), the diagnostic
359 potential of anti-measles dIgA as determined using AUC did not outperform the
360 commercial anti-measles VL and NP IgM assays due to a small number of high false
361 positives observed in samples of patients with other viral exanthematous infections
362 (Figure 1, Table 1).

363

364 These differences in dIgA reactivity among measles-infected subjects can be
365 explained by three underlying possibilities: 1) variability in antigen preparation
366 between commercial and in-house VL ELISA plates, 2) saturation or competition of
367 binding sites in NP by IgM, and 3) dIgA is made as part of early transitory response
368 against specific antigens in lysate, rather than against NP.

369

370 Given that immobilization on the solid phase is a key source of assay variability,
371 especially for crude lysate preparations, it is likely that the lysate used to prepare in-
372 house plates differed significantly in composition of individual proteins and the
373 amount used to coat plates compared to the VL used in the commercial plates from
374 Euroimmun and Micromimmune. Indeed, even within the same manufacturer, batch-
375 to-batch variation of antigen-coated plates has been recorded with significant
376 differences in diagnostic performance observed (11). Since the plates from
377 Euroimmun were part of an ELISA kit to specifically detect IgM, it is possible that the
378 lysate preparation and kit components on the Euroimmun plates were optimized for
379 IgM binding, leading to a saturation of binding sites by IgM.

380

381 We have seen from previous studies in the laboratory that the current dIgA assay
382 requires longer incubation time for efficient antigen binding, in part due to the cSC
383 detection protein that selects for dIgA requiring a conformational change upon
384 binding (21), especially when the antigen is immobilized on a solid phase. Thus, it is
385 possible that the reduced reactivity observed on the Euroimmun plates reflect
386 selective binding and consequent saturation of anti-VL IgM on antigens before any
387 anti-VL dIgA present could effectively bind, rather than absence of the latter.

388

389 Related to this, where we saw high dIgA reactivity against measles VL antigens, we
390 observed lower dIgA reactivity against the measles NP antigen. Similarly with the VL,
391 there is possibility that the IgM present at higher levels (as suggested by the ODs in
392 Figure 2) is saturating binding sites and out-competing the dIgA antibodies. While it
393 is more difficult to pursue for a crude antigen such as VL, a dIgA capture assay for
394 NP and modifications to the sample buffer to remove competing antibodies of other

395 classes could be explored, which we have shown previously in acute hepatitis E
396 samples and COVID-19 samples to be an effective way to isolate dIgA responses
397 against a purified antigen (16, 17). Furthermore, a capture assay is the preferred
398 format for future translation to a lateral flow platform, which arguably is the ideal
399 point-of-care test type for improved global measles detection and surveillance (7).

400

401 Besides potential binding site competition, which we could not rule out in this
402 investigation, we also hypothesize that the lack of dIgA reactivity to measles NP,
403 despite it being the most abundant protein in infected cells and its presence in high
404 quantities in VL (22), suggests that most dIgA recognition is towards surface
405 exposed antigens such as H & F present in the VL (23). This aligns with the idea that
406 dIgA is generated as part of early immune response as seen in COVID-19 (14), and
407 thus less likely to recognize NP, which is enclosed within virus nucleocapsid and
408 only released upon lysis of infected cells (22, 23). We cannot yet explain why we
409 observed higher false positives in the dIgA assays from non-measles controls
410 representing infections with other viruses of exanthematous conditions included in
411 the control group, but this may be due to cross-reactivity to cellular proteins in the
412 crude VL protein preparations.

413

414 That said, the dIgA assay has been successfully used to demonstrate elevated
415 levels of anti-measles VL dIgA in measles serum/plasma samples compared to
416 various non-measles controls with an AUC of 0.948, and a corresponding 76%
417 sensitivity at 95% specificity. The development of purified antigens such as F & H
418 proteins, which remains commercially unavailable, will be critical to overcome the
419 limitations of relying on crude antigens such as the measles VL. With better purified
420 antigens, assay optimisation could be pursued to overcome background issues by
421 increasing signal from true positive samples, reduce non-specific binding, and
422 optimize the assay on capture formats, which arguably will increase sensitivity and
423 specificity of dIgA as a novel blood-based marker of measles.

424

425

426

427

428 **Conclusion**

429

430 Dimeric IgA in blood has now been observed in various viral infections (16, 17).
431 While the literature is rich with characterizations of mucosal immunity and IgA in
432 secretions and mucosal surfaces (24), there are significant gaps in understanding of
433 dIgA as a serological biomarker. We show that anti-measles VL dIgA is detectable in
434 high levels in serum/plasma of measles cases, and is likely to be part of an early
435 response to infection that is independent from IgM production. The diagnostic
436 potential of anti-measles VL dIgA may be enhanced with optimization of antigen

437 preparation to increase separation of measles samples from non-measles controls
438 and reducing competition from other antibody classes. Our novel approach to
439 measuring dIgA response in blood may enable further examination of dIgA
440 responses to measles and uncover new aspects of mucosal immunity for this priority
441 disease.

442

443

444

445 **Funding**

446 The authors would like to acknowledge funding from the Victoria-Jiangsu Technical
447 Cooperation grant and we also gratefully acknowledge the contribution to this work
448 of the Victorian Operational Infrastructure Support Program (Australia) received by
449 the Burnet Institute. This study was also supported by the operating funds of the
450 Viral Exanthemata and STD Section at the National Microbiology Laboratory,
451 Manitoba, Canada.

452

453

454 **Acknowledgments**

455 The authors would like to thank Irene Boo, Rob Center, Zihui Wei and Peter
456 Newman of Burnet Institute, Vicki Stambos and Suellen Nicholson of VIDRL, Wayne
457 Dimech and Joe Vincini of the Australian NRL, Brian Cao of Boint Biotech and other
458 collaborating organizations for provision of samples and reagents for this study.

459

460 **References**

- 461 1. WHO. 2020. Measles and Rubella Strategic Framework 2021-2030. World
462 Health Organization, Geneva.
- 463 2. Sartorius B, Cohen C, Chirwa T, Ntshoe G, Puren A, Hofman K. 2013.
464 Identifying high-risk areas for sporadic measles outbreaks: lessons from South
465 Africa. *Bull World Health Organ* 91:174–183.
- 466 3. Fappani C, Gori M, Canuti M, Terraneo M, Colzani D, Tanzi E, Amendola A,
467 Bianchi S. 2022. Breakthrough Infections: A Challenge towards Measles
468 Elimination? *Microorganisms* 10:1567.
- 469 4. Bianchi FP, Mascipinto S, Stefanizzi P, De Nitto S, Germinario C, Tafuri S.
470 2021. Long-term immunogenicity after measles vaccine vs. wild infection: an
471 Italian retrospective cohort study. *Hum Vaccin Immunother* 17:2078–2084.
- 472 5. Sasaki H, Fukunaga T, Asano A, Suzuki Y, Nakanishi Y, Kondo J, Ishikawa H,
473 Shibata N. 2019. A Survey of Vaccine-Induced Measles IgG Antibody Titer to
474 Verify Temporal Changes in Response to Measles Vaccination in Young
475 Adults. *Vaccines* 7:118.
- 476 6. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S,
477 Gargiullo P. 2007. Persistence of Measles Antibodies After 2 Doses of
478 Measles Vaccine in a Postelimination Environment. *Arch Pediatr Adolesc Med*
479 161:294.
- 480 7. Gastañaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA,

- 481 Patel M. 2021. Measles in the 21st Century: Progress Toward Achieving and
482 Sustaining Elimination. *J Infect Dis* 224.
- 483 8. Cui A, Mao N, Wang H, Xu S, Zhu Z, Ji Y, Ren L, Gao L, Zhang Y, Xu W.
484 2018. Importance of real-time RT-PCR to supplement the laboratory diagnosis
485 in the measles elimination program in China. *PLoS One* 13:e0208161.
- 486 9. Mercader S, Garcia P, Bellini WJ. 2012. Measles Virus IgG Avidity Assay for
487 Use in Classification of Measles Vaccine Failure in Measles Elimination
488 Settings. *Clin Vaccine Immunol* 19.
- 489 10. Brown DW, Warrener L, Scobie HM, Donadel M, Waku-Kouomou D, Mulders
490 MN, Rota PA. 2020. Rapid diagnostic tests to address challenges for global
491 measles surveillance. *Curr Opin Virol* 41.
- 492 11. Hiebert J, Zubach V, Charlton CL, Fenton J, Tipples GA, Fonseca K, Severini
493 A. 2021. Evaluation of Diagnostic Accuracy of Eight Commercial Assays for
494 the Detection of Measles Virus-Specific IgM Antibodies. *J Clin Microbiol* 59.
- 495 12. Warrener L, Bwogi J, Andrews N, Samuel D, Kabaliisa T, Bukenya H, Brown
496 K, Roper MH, Featherstone DA, Brown D. 2018. Serum anti-tetanus and
497 measles antibody titres in Ugandan children aged 4 months to 6 years:
498 implications for vaccine programme. *Epidemiol Infect* 146.
- 499 13. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. 2020. Mucosal Immunity in
500 COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. *Front*
501 *Immunol* 11.
- 502 14. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah
503 J, Devilliers H, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt C-
504 E, Mayaux J, Beurton A, Fourati S, Bruel T, Schwartz O, Lacorte J-M, Yssel H,
505 Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochov G. 2021. IgA
506 dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl*
507 *Med* 13.
- 508 15. Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R,
509 Levine MM, Pasetti MF. 2011. Mucosal IgA Responses in Healthy Adult
510 Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles
511 Vaccine. *Clin Vaccine Immunol* 18:355–361.
- 512 16. Mohd Hanafiah K, Garcia ML, Barnes NC, Anderson DA. 2018. Detection of
513 virus-specific polymeric immunoglobulin A in acute hepatitis A, C, E virus
514 serum samples using novel chimeric secretory component. *BMC Res Notes*
515 11.
- 516 17. Drummer HE, Van H, Klock E, Zheng S, Wei Z, Boo I, Center RJ, Li F, Bhat P,
517 Ffrench R, Lau JS, McMahon J, Laeyendecker O, Fernandez RE, Manabe YC,
518 Klein SL, Quinn TC, Anderson DA. 2021. Dimeric IgA is a specific biomarker of
519 recent SARS-CoV-2 infection. *medRxiv*.
- 520 18. Wei Z, Angrisano F, Eriksson EM, Mazhari R, Van H, Zheng S, Center RJ,
521 McMahon J, Lau J, Kiernan-Walker N, Ruybal-Pesántez S, Mueller I, Robinson
522 LJ, Anderson DA, Drummer HE. 2023. Serological assays to measure dimeric
523 IgA antibodies in SARS-CoV-2 infections. *Immunol Cell Biol*
524 <https://doi.org/10.1111/imcb.12682>.
- 525 19. Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P, Beard F.
526 2022. Australian vaccine preventable disease epidemiological review series:
527 measles, 2012–2019. *Commun Dis Intell* 46.
- 528 20. Thomas H. 1999. Simultaneous IgM reactivity by EIA against more than one

- 529 virus in measles, parvovirus B19 and rubella infection. *J Clin Virol* 14:107–118.
- 530 21. Stadtmueller BM, Huey-Tubman KE, López CJ, Yang Z, Hubbell WL,
531 Bjorkman PJ. 2016. The structure and dynamics of secretory component and
532 its interactions with polymeric immunoglobulins. *Elife* 5.
- 533 22. Šantak M, Matic Z. 2022. The Role of Nucleoprotein in Immunity to Human
534 Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral
535 Nucleocapsid. *Viruses* 14:521.
- 536 23. Laine D, Trescol-Biémont M-C, Longhi S, Libeau G, Marie JC, Vidalain P-O,
537 Azocar O, Diallo A, Canard B, Rabourdin-Combe C, Valentin H. 2003. Measles
538 Virus (MV) Nucleoprotein Binds to a Novel Cell Surface Receptor Distinct from
539 FcγRII via Its C-Terminal Domain: Role in MV-Induced Immunosuppression. *J*
540 *Virol* 77:11332–11346.
- 541 24. Li Y, Jin L, Chen T. 2020. The Effects of Secretory IgA in the Mucosal Immune
542 System. *Biomed Res Int* 2020:1–6.
- 543